1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Mean rCBV ratio between pseudoprogression and real progression
No. rCBV 95% CI P Value
Unmethylated group 22 .009
    Pseudoprogression 4 0.87 0.10–1.63 
    Real progression 12 3.25 1.46–5.04 
Methylated group 26 .258
    Pseudoprogression 9 1.56 0.57–2.55 
    Real progression 7 2.34 1.05–3.61
	No.	rCBV	95% CI	P Value
Unmethylated group	22			.009
Pseudoprogression	4	0.87	0.10–1.63
Real progression	12	3.25	1.46–5.04
Methylated group	26			.258
Pseudoprogression	9	1.56	0.57–2.55
Real progression	7	2.34	1.05–3.61